Exact Sciences Beats Q2 Estimates Despite a COVID-19 Drag

Exact Sciences (NASDAQ:EXAS) hasn't fired up investors so far in 2020 like it did last year. But the COVID-19 pandemic has weighed heavily on the cancer screening and diagnostics provider's business. The good news is that Exact Sciences' management team said that there were signs of improvement in the quarterly conference call in May.